cyrilzakka/clinical-trials huggingface dataset:
The Effect of Branched-chain Amino Acid (BCAA) on the Progression of Primary Liver Cancer

Supplementation of BCAA found to reduce the risk of developing liver cancer, but the affect of BCAA on existing liver cancer is unknown.

The participants (post curative intent surgery) will be supplemented with either BCAA/non-BCAA-enriched protein supplement. The intervantion will go on for 2 years or until a new liver tumor is found.


Eligibility Criteria:
Inclusion Criteria:

* diagnosed primary liver cancer
* viral or Nonalcoholic Steatohepatitis Cirrhosis
* Cirrhosis rated Child-Pugh A
* liver cancer rated Barcelona Clinic Liver Cancer (BCLC) A

Exclusion Criteria:

* Age (over 65)
* liver condition rated Child-Pugh B/C
* GI/Absorption issues
* patients given a treatment before surgery
Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas

This study is designed as a multi-centre randomized, open label trial to compare the safety and efficacy of a high dose primaquine (PQ) treatment in G6PD normal patients with P. falciparum to reduce the risk of subsequent P. vivax episodes to current standard practice of providing only schizontocidal treatment.

Plasmodium vivax forms dormant liver stages that reactivate weeks or months following an acute infection. Recurrent infections can be associated with a febrile illness, a cumulative risk of severe anaemia, direct and indirect mortality, and are the most important source of onward transmission of the parasite. In co-endemic areas, there is a very high risk (up to 50%) of patients representing with P. vivax malaria following treatment of P. falciparum. Hence, in co-endemic regions there is a strong rationale for eradicating P. vivax hypnozoites from the liver in patients presenting with uncomplicated P. falciparum infections.

The recently completed multicentre IMPROV study compared the efficacy of a 7 day primaquine regimen (1.0 mg/kg/day for 7 days) with a 14 day regimen (0.5 mg/kg/day for 14 days). The 7 day PQ regimen was non-inferior to the 14 day regimen and 5-fold more efficacious at reducing P. vivax recurrence than the control.

This study is designed as a multicentre randomized, open label trial to compare the safety and efficacy of a high dose PQ treatment in G6PD normal patients with P. falciparum to reduce the risk of subsequent P. vivax episodes to current standard practice of providing only schizontocidal treatment.

Eligibility Criteria:
Inclusion Criteria:

* P. falciparum mono-infection
* Fever (axillary temperature ≥37.5⁰C) or history of fever in preceding 48 hours
* Age \>1 years (≥ 18 years at the Ethiopia site)
* G6PD normal as defined by the Biosensor (SD Biosensor, ROK) at ≥70% of the adjusted male median (AMM) for each site
* Written informed consent
* Able to comply with all study procedures and timelines

Exclusion Criteria:

* General danger signs or symptoms of severe malaria
* Anaemia, defined as Hb \<8g/dl
* Pregnant women as determined by Urine β-HCG pregnancy test
* Breast feeding women
* Known hypersensitivity to any of the drugs given
* Regular use of drugs with haemolytic potential
* Blood transfusion within the last 4 months
Effect of Pelvic Control Exercises in Stroke

The purpose of the study is to investigate the combined effect of pelvic and trunk control exercises on muscle performance of affected upper extremity in stroke patients.

The study conducted on forty stroke patients. They assessed by Biodex System 3 Pro Isokinetic, Modified Ashworth Scale(MAS), Fugel Meyer Assessment scale (FMAS), Box and block test and hand grip dynamometer. Patients divided into control group and study group. The control group treated by a traditional physical therapy program.The study group treated by the traditional physical therap program in addition to pelvic and trunk control exercises for 40 min.

Eligibility Criteria:
Inclusion Criteria:

* Patient's age will range from 45 - 60 years.
* Muscle tone grade will range from 1 to 1+ according to modified Ashworth scale.
* Duration of illness will range from 6 to 18 months after stroke onset.
* Ability of the patient to stand without assistive devices.

Exclusion Criteria:

* • Other neurological or musculoskeletal disorders that might affect pelvic alignment such as severe arthritis, knee surgery, total hip joint replacement, lower limb fractures, contractures of fixed deformity or leg length discrepancy.

  * Severe chronic back and/or knee pain that might affected standing posture.
  * Recurrent stroke
  * Shoulder or upper limb injury that might affect the recovery.
  * Perceptual or cognitive dysfunctions.
  * BMI \> 30
Epidemiological Characteristics of Elderly Trauma Patients in Zhejiang Province and Development of Geriatric Trauma Short-term Mortality Prediction Model

This is a retrospective study. Trauma patients aged 65 years or older will be included. The aims of this study are explore the epidemiological characteristics of elderly trauma patients in Zhejiang Province; establishment of early warning score system of elderly trauma death in Zhejiang Province; and horizontal comparison of the treatment level of elderly trauma in Zhejiang Province.


Eligibility Criteria:
Inclusion Criteria:

Trauma patients aged 65 years or older

Exclusion Criteria:

Secondary trauma due to other causes
Multicenter Assessment of Clinical Utility PET / MR With the Use of the Radiotracer 68Ga-PSMA-11 in Therapy Planning Personalized in Patients With Prostate Cancer

The aim of multicentre phase 3 trial is evidence diagnostic value of 68Ga-PSMA-11 (in PET / CT and PET / MR techniques) in patients with high-risk and intermediate prostate cancer before radical treatment and in diagnosed patients biochemical recurrence after radical treatment


Eligibility Criteria:
Inclusion Criteria:

Group 1. Patients with diagnosis or high probability of medium and high prostate cancer according International Society of Urological Pathology (ISUP) risk for whom radical treatment is planned

* Prostate adenocarcinoma confirmed by biopsy and histopathological examination
* Results indicating a moderate RGK (Gleason score 7 or cT2b or PSA 10-20 ng / ml) or high (Gleason score\> 7 or cT2c or PSA\> 20 ng / ml) risk according to ISUP
* Creatinine value allowing for safe PET / MR examination with a contrast agent: creatinine less than or equal to 1.5 times the upper limit of normal, creatinine clearance\> 60 mL / min
* Age ≥18 years
* Signing informed consent to participate in the study
* Pelvic / prostate mpMR examination performed, not earlier than 30 days before inclusion in the study

Group 2. Patients with RGK after radical treatment, with biochemical recurrence according to EAU criteria, who are scheduled for further treatment and the result of the imaging / molecular examination may affect change of therapeutic decision:

* Prostate adenocarcinoma confirmed by biopsy and histopathological examination
* After radical treatment
* In patients after radical prostatectomy: with at least two PSA measurements ≥0.2 ng / ml not earlier than after 6-13 weeks after radical prostatectomy or PSA≥0.1 with PSAdt (PSA doubling time) \<3 months PSA on at least two consecutive studies in consecutive last 6 months before qualification (last determination within 6 weeks before qualification) Or
* In patients after radical radiotherapy: biochemical recurrence defined as nadir PSA + 2 ng / ml
* Age ≥18 years
* Signing informed consent

Exclusion Criteria:

* Presence of metallic foreign bodies / implants / prostheses / stimulators etc. inside the body, the possession of which is a contraindication to the MR 3T examination
* Claustrophobia
* Patient size precluding PET / MR examination due to diameter gantry
* Known contraindications for the use of radiopharmaceuticals or substances auxiliary (e.g. renal failure and allergy to ingredients in the preparation)
* Treatment for malignant neoplasm not associated with the prostate gland
* Participating in another clinical trial
* Lack of informed consent to participate in the study
* Age \<18 years
Study to Investigate Safety, Tolerability and Pharmacokinetics With Single and Multiple Ascending Doses of AZD1446

This study is designed to evaluate the safety, tolerability and PK of AZD1446 in Subjects when given as multiple dose administration for either 7 Days (Day 1 single dose, Day 2-6 multiple doses) in Part A and optionally at fractionated doses for 1 Day in Part B.


Eligibility Criteria:
Inclusion Criteria:

* Male or non-fertile female, young or elderly Subjects, aged ≥18 to ≤50 or ≥65 to ≤80
* Body mass index (BMI) between 19 and 30 kg/m2
* Clinically normal findings on physical examination

Exclusion Criteria:

* History of any clinically significant disease or disorder
* History of severe allergy/hypersensitivity reactions
Effect of Rectal Misoprostol in Reducing Intra-operative Blood Loss During Myomectomy

A total of 200 women for elective abdominal myomectomy were randomly allocated into two groups.

100 women in experimental group were administered 400ug Misoprostol (2 tablets of Prosotec®) through the rectal route prior to surgery and 100 were in control group, in which no drug was administered.

After getting approval from hospital's ethical committee, patients eligible for the study were recruited in the study according to the selection criteria. Before surgery, after taking informed written consent, patient's detailed history including demographics, parity \& BMI was recorded. Uterine size was assessed by bimanual pelvic examination. Patients undergoing myomectomy were randomly divided into 2 groups using lottery method. In experimental group Misoprostol 400ug was administered per rectally prior to surgery. In control group, no drug was administered.

The surgical procedural elements, the surgeon or surgeons performing the procedure and the use of antibiotics as well as anesthetic agents was standardized to remove any bias. Intraoperative blood loss was recorded by a single trained doctor and calculated using visual scale for the abdominal sponges and chest swabs/gauzes used during surgery and blood collected in suction bottle.

Eligibility Criteria:
Inclusion Criteria:

1. ASA physical status class I-II
2. Intramural or subserosal fibroids - diagnosed on ultrasound
3. Candidates for elective abdominal myomectomy

Exclusion Criteria:

1. Pre-operative Hemoglobin \< 10 g/dl
2. Patient who received Danazol or GnRH analogues before surgery
3. No other systemic or metabolic disease
Saturated Fatty Acids Intake and Mortality, Diabetes, Hypertension and Overweight

The role of saturated fatty acids (SFAs) intake in the development of total death, cardiovascular diseases, diabetes, hypertension and overweight are in great controversy but evidence from large population in China is scant.The investigators aim to use the data from the China Health and Nutrition Survey to assess the long-term association of SFAs intake with total mortality, diabetes, hypertension and overweight.

The role of saturated fatty acids (SFAs) intake in the development of total death, diabetes, hypertension and overweight are in great controversy but evidence from large population in China is lacking.The investigators aim to utilize the data from the China Health and Nutrition Survey. The investigators will calculate the cumulative average intake of SFAs based on 3 consecutive 24-h dietary recalls in each round.Sex-specific Cox regression models will be used to estimate the relative risk.Results from our work will be used to provide epidemiological evidence for improving recommendation on SFAs intake for Chinese in dietary guidelines.

Eligibility Criteria:
Inclusion Criteria:

* Adults aged ≥20 with complete data on diet and follow-up time

Exclusion Criteria:

* Cardiovascular diseases
* Diabetes (for analyses of diabetes)
* Body mass index ≥ 24 kg/㎡ (for analyses of overweight)
* Hypertension (for analyses of hypertension)
Evaluation of Patients With Diffuse Parenchymal Lung Diseases Regarding Frailty

There are very few studies in the literature examining the frailty levels of diffuse parenchymal lung disease (DPLD) patients and its effect on their functional status despite the high prevalance of frailty in patients with DPLD This observational study aims to learn about the relationship between frailty and functional capacity and balance in DPLD patients compared to healthy subjects.

The aim of the study is to evaluate the relationship between the level of frailty and exercise capacity, respiratory functions, diffusion capacity, balance level, postural changes, activities of daily living, peripheral muscle strength and quality of life parameters in DPLD patients. The second aim is to compare diffuse parenchymal lung patients and the healthy control group in terms of these parameters.

Eligibility Criteria:
Inclusion Criteria:

* Being diagnosed with Diffuse parenchymal lung according to the American Thoracic Society/European Respiratory Society (ATS/ERS) criteria,
* Being between the ages of 30-65,
* Being literate,
* Being willing to participate in the research,
* Being clinically stable and having any accompanying comorbid conditions (such as hypertension, diabetes) under control,
* Not having any orthopedic, metabolic or neurological problems that may prevent evaluation of peripheral muscle strength, balance and exercise capacity.

Exclusion Criteria:

* Having recently experienced syncope,
* Having a history of unstable cardiovascular disease,
* Having been hospitalized due to exacerbation in the last 3 months,
* Having received pulmonary rehabilitation in the last 12 months,
* Having a neurological disease,
* Being dependent and using a walking aid while performing the person's daily life activities,
* Having a pacemaker,
* Having a diagnosis of lung cancer
Carbamazepine Treatment for Cocaine Dependence - 5

The purpose of this study is to assess carbamazepine as a pharmacotherapy for cocaine dependence.


Eligibility Criteria:
Please contact site for information.
Study of Abdominal Aortic Stent Grafts in the Treatment of Infrarenal Abdominal Aortic Aneurysms

The Vascutek Anaconda™ Stent Graft System for repair of Abdominal Aortic Aneurysms (AAA) is the subject of this observational study. 180 patients will be implanted with the Anaconda™ Stent Graft System and will be followed-up annually for 5 years post-implant. The study will satisfy the requirements of the French National Authority for Health (Haute Autorité de santé) and the data collected will be used for reimbursement renewal.

Infrarenal abdominal aortic aneurysms may be treated with the introduction of an abdominal aortic stent graft via the femoral route. This technique is commonly used in high surgical risk patients but can also be suitable under certain conditions for normal risk patients.

Abdominal aortic stent grafts, inserted via the femoral artery, are used to treat infrarenal abdominal aortic aneurysms, removing the need for an invasive surgical procedure.

The aim of this observational study is to evaluate the long-term (5 year) benefits of the technique by documenting the overall mortality, complications (endoleak, migration), rate of surgical conversion, progression and rupture of the aneurysm in a cohort of patients who are representative of the treated population under real conditions of use.

Eligibility Criteria:
Inclusion Criteria:

* Any patient implanted with the Vascutek Anaconda™ Stent Graft System for the treatment of a non-ruptured infrarenal Abdominal Aortic Aneurysm (AAA)

Exclusion Criteria:

* Patients for whom clinical follow-up is impossible and cannot return for check-up visits
Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSCLC

Consolidation immunotherapy of immune checkpoint inhibitor (ICI) following chemoradiotherapy (CRT) is the current standard of care for patients with unresectable locally advanced non-small cell lung cancer (NSCLC) as it improves both progression-free survival and overall survival. However, a substantial proportion of patients still experience disease recurrence despite consolidation ICI. It is important for personalized treatment to predict the efficacy of consolidation ICI. PD-L1 expression is used as a predictive biomarker for ICI response and efficacy in advanced NSCLC, but its role in patients with stage III disease is unclear. One important reason is PD-L1 testing performed on pre-CRT tissue may not reflect changes in PD-L1 expression after CRT. CT-based radiomics approaches have been successfully applied to generate imaging biomarkers as decision support tools for clinical practice. The hypothesis of this study is that CT radiomics model can assess PD-L1 status after CRT and predict the efficacy of CRT combined with ICI in unresectable locally advanced NSCLC.

This is an observational longitudinal prospective study.

CT scan is performed before radiotherapy, during radiotherapy and at the end of radiotherapy in patients with unresectable locally advanced NSCLC who undergo CRT. Radiomic features were extracted from CT images and baseline PD-L1 expression is assessed. CT-based radiomics models is developed to assess PD-L1 expression and predict the efficacy of ICI.

Eligibility Criteria:
Inclusion Criteria:

* Histological or cytological proven non-small cell lung cancer
* Unresectable stage III according to American Joint Committee of Cancer stage (the eighth edition)
* 18 years or older

Exclusion Criteria:

* Previous thoracic radiotherapy
* Palliative treatment
HYPERTENSIVE CRISIS AND ATMOSPHERIC PRESSURE RELATIONSHIP

relationship between the onset times of symptoms and the regions of patients presenting to the emergency department with hypertensive crisis (systolic ≥180 and/or diastolic ≥110 mmHg) and the fluctuations in atmospheric pressure

Hypertensive emergency is defined as grade 3 hypertension (systolic ≥180 and/or diastolic ≥110 mmHg) that causes end-organ damage, requiring urgent intervention and intensive care admission . Hypertensive crisis is described as severe hypertension not associated with end-organ damage. Some sources define hypertensive crisis as hypertension of grade 3 or higher, while others refer to it as severe hypertension without specifying a threshold .

Literature reviews, published guidelines, and studies indicate that the definitions and treatment approaches for hypertensive crisis differ between Europe and America, with variations in management from one physician to another . Seasonal blood pressure fluctuations are influenced by external temperature, indoor temperature, humidity, atmospheric pressure, and wind . Notably, during periods of low atmospheric pressure, blood pressure measurements show statistically significant increases compared to other days . Consequently, the frequency of life-threatening conditions associated with hypertension, such as intracranial hemorrhage and abdominal aortic aneurysm rupture, has been observed to increase on days when atmospheric pressure changes .

In our study, we aim to investigate the relationship between the onset times of symptoms and the regions of patients presenting to the emergency department with hypertensive crisis (systolic ≥180 and/or diastolic ≥110 mmHg) and the fluctuations in atmospheric pressure

Eligibility Criteria:
Inclusion Criteria:

1. Age 18 and above
2. Hypertensive crisis (systolic ≥180 and/or diastolic ≥110 mmHg)

Exclusion Criteria:

1. Patients presenting with hypertensive emergency (those with end-organ damage)
2. Patients who have traveled to another city or district within the last 4 days
3. Pregnant patients
Nutrition Labeling Program to Promote Healthy Dietary Patterns

This study aims to evaluate a nutrition labelling program in improving university canteen customers' dietary pattern and behavioural determinants (e.g. knowledge).

The increase in diet related diseases worldwide is considered to be primarily caused by a changing environment encouraging high energy intakes and a sedentary lifestyle. Examples of important environmental factors are the changing nature of the food supply, the changing socio-demographic structure of the population, the lack of nutrition information and the increasing reliance on foods consumed away from home. This evolution has driven the development of measures to encourage more healthy eating patterns. Nutrition labelling is one of those measures. Since adults and students spend approximately half their waking hours at the workplace or university, the work or study environment is believed to be an appropriate setting to assess and try to change individuals' dietary behaviour. This study aims to evaluate a nutrition labelling program in improving university canteen customers' dietary pattern and behavioural determinants (e.g. knowledge).

Eligibility Criteria:
Inclusion Criteria:

* university students and staff
* frequent university canteen customers
* willing to participate

Exclusion Criteria:

* non-frequent university canteen customers
Long-Term Open-Label Extension Trial for Subjects Completing the Phase 3 Trial of Fesoterodine (SP584) for the Treatment of Overactive Bladder Syndrome

This trial will provide long-term data on safety, satisfaction and maintenance on therapy of fesoterodine (SPM 907) in subjects with overactive bladder syndrome.

Subjects completing the 12 week treatment period of SP584 had the opportunity to participate if eligibility was confirmed. They received fesoterodine 8mg with the option to reduce the dose to 4mg during scheduled visits, and to increase again to 8mg, a procedure which can be followed on an annual basis.

The primary variables are long-term safety and tolerability, measured by observation and assessment of adverse events and duration on therapy. Further safety variables include the assessment of laboratory parameters, changes in ECG, physical exams and measurement of residual urine.

Secondary efficacy variables included various parameters derived from micturition diaries and the evaluation of Quality of Life questionnaires


Eligibility Criteria:
Inclusion Criteria:

* Overactive Bladder Syndrome
Reproductive Outcome Affected by Two Adjunctive Treatments in Patients With Severe Intrauterine Adhesions

The purpose of this study is to compare the outcome of loop intrauterine contraceptive device and heart-shaped intrauterine balloon for the adjunctive treatment of severe intrauterine adhesions in patients with infertility.

Intrauterine adhesion, also known as Asherman's syndrome, is the partial or complete occlusion of the uterine cavity as a result of endometrium damage. Most intrauterine adhesions patients manifest amenorrhea, reduced menstrual pattern, infertility, and intrauterine growth restriction, which seriously affect their reproductive health. Currently, hysteroscopy is the preferred method of intrauterine adhesions diagnosis and treatment. However, because intrauterine adhesions patients generally have poor endometrium repair capability, the incidence rate of reformation of intrauterine adhesions ranging from 20%-62.5% in those with severe adhesions. The successful pregnancy rate after treatment in severe Asherman's syndrome is reported to be consistently lower, only 33%. The prevention of intrauterine adhesions recurrence after trans-cervical resection of adhesion is clinically important but difficult. Therefore, this study was conducted.

Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of severe intrauterine adhesions
* infertility

Exclusion Criteria:

* endometrial tuberculosis
* grossly abnormal semen analysis
* ovarian failure, hydrosalpinx fluid
* patients who did not proceed to second-look hysteroscopy within the specified time frame
* Women with no desire to pregnancy